Donor pretreatment with ProGP-1 allows escalation of graft cell dose above that possible with donor pretreatment with G-CSF.
(A-B) Survival curves by Kaplan-Meier analysis, pooled from 3 similar experiments. Donor B6 mice were treated as in Figure 3. Splenocytes were harvested on day 11 and transplanted into lethally irradiated B6D2F1 recipient mice at doses of 4 × 106/animal (for G-CSF group only, n = 10), 10 × 106/animal (n = 10-20), 60 × 106/animal (n = 10-15), and 100 × 106/animal (n = 10). This equates to T-cell doses of 1.2 × 106, 3.0 × 106, 18 × 106, and 30 × 106 in G-CSF–treated donors and 1.2 × 106, 7.2 × 106, and 12 × 106 in ProGP-1–treated donors.P < .03 for all G-CSF versus ProGP-1 (10 × 106 and 60 × 106). *P = .26 for G-CSF (10 × 106) versus ProGP-1 (100 × 106). (C) GVHD clinical scores as described in “Materials and methods” were determined as a measure of GVHD severity in surviving animals. *P < .05 for G-CSF (10 × 106) versus ProGP-1 (60 × 106) and **P < .01 for G-CSF (10 × 106) versus ProGP-1 (10 × 106) at the time points indicated.
